The Centers for Disease Control and Prevention’s (CDC) vaccine advisory committee is set to meet this Thursday and Friday to review aspects of the childhood immunization schedule, including the hepatitis B vaccine given to newborns, reports Baltimore Chronicle. While the draft agenda provides limited details on presentations or speakers, it specifically notes discussion and potential votes regarding the hepatitis B vaccine.
Though the precise motions to be voted on are unclear, past remarks from Health and Human Services Secretary Robert F. Kennedy Jr. and members of the Advisory Committee on Immunization Practices (ACIP) suggest that the universal birth dose of the hepatitis B vaccine could be reconsidered. The ACIP may vote to remove the recommendation for vaccination at birth or postpone it to a later age.
Public health officials emphasize that there is no evidence suggesting the hepatitis B vaccine is unsafe. Vaccination at birth has played a critical role in drastically reducing the incidence of hepatitis B among children.
The hepatitis B vaccine is administered as a three-dose series. The CDC recommends the first dose within 24 hours of birth, the second between one and two months, and the third between six and 18 months. In addition to all infants, the vaccine is recommended for children and adults up to age 59, and adults 60 and older with risk factors for hepatitis B.
Originally, only infants identified as high risk were vaccinated, but screenings missed many cases, prompting the ACIP to recommend universal vaccination at birth in 1991. Dr. Susan Wang, a former CDC hepatitis B expert, noted that decades of research confirm both the safety and effectiveness of early vaccination.
Dr. William Schaffner, professor of preventive medicine at Vanderbilt University Medical Center, explained the significance of the birth dose. If a mother is hepatitis B-positive, the newborn has an 85% chance of developing infection, which carries a 90% risk of chronic hepatitis B, potentially leading to cirrhosis, liver disease, or cancer.
Before the universal recommendation in 1991, up to 20,000 babies annually contracted hepatitis B from their mothers. Today, fewer than 20 infants per year are infected this way. Experts describe the program as highly successful, warning that delaying vaccination could result in children missing their birth dose and maintaining transmission in the population.
Opponents, including RFK Jr., have falsely linked the vaccine to autism and suggested only babies of infected mothers should receive it. However, studies consistently show no connection between vaccines and autism. Experts stress that a testing-only approach fails because not all mothers are screened or results are delayed, leaving newborns unprotected.
The birth dose acts as post-exposure prophylaxis for newborns potentially exposed from their mothers, and it also prevents infection from other contacts during early infancy. Delaying or eliminating the universal dose could compromise long-term public health efforts to interrupt hepatitis B transmission.
Insurers often follow ACIP recommendations. Any changes could affect coverage, requiring parents to pay out-of-pocket or excluding vaccines from the federally funded Vaccines for Children program, which provides free vaccines to eligible children.
Earlier we wrote that Presidential HIV Council Warns Federal Cuts Could Threaten Decades of HIV Progress.
